Anogen-Yes Biotech

01/28/2026

A Cell Perspective outlines how the field is evolving beyond traditional amyloid-focused treatments to include tau-targeted approaches, neuroinflammation modulation, and multi-modal strategies that better address the complexity of Alzheimer’s disease. These insights highlight a broader therapeutic landscape with potential for future breakthroughs.

Read the full article: https://www.cell.com/cell/fulltext/S0092-8674(25)01368-6

Emerging tau-targeting approaches show promise in slowing Alzheimer’s disease progression, complementing recent advances in FDA-approved anti-Aβ therapies. This perspective outlines the progress in Alzheimer’s disease therapeutic development, highlighting how tau trial outcomes are providing in...

01/22/2026

An early-stage clinical trial has shown that VY7523, an investigational anti-tau agent, demonstrated a positive safety and tolerability profile in patients with early Alzheimer’s disease. As tau pathology is strongly linked to neurodegeneration and cognitive decline, these findings support continued exploration of tau-targeted therapies as a promising avenue beyond amyloid-focused approaches.

🔬 Early safety success is a critical step toward developing disease-modifying treatments for Alzheimer’s.

Read the full article here: https://www.neurologylive.com/view/anti-tau-agent-vy7523-demonstrates-positive-safety-early-alzheimer-trial

Overall, treatment with the anti-tau monoclonal antibody resulted in no serious or severe adverse events, with additional results expected to be presented at an upcoming scientific conference.

01/14/2026

Anti-amyloid monoclonal antibodies—like lecanemab and donanemab—are changing the landscape of Alzheimer’s disease care by targeting amyloid-β plaques, a core driver of disease. These therapies have shown robust plaque removal and modest slowing of cognitive decline in early AD patients with confirmed amyloid pathology. While challenges remain, this progress marks a pivotal step toward precision neurology and more effective, tailored interventions for Alzheimer’s.

Read the full article here: https://pmc.ncbi.nlm.nih.gov/articles/PMC12470750/

Alzheimer’s disease (AD) is the most common cause of dementia, pathologically defined by extracellular amyloid-β (Aβ) plaques and intracellular tau neurofibrillary tangles. Recent U.S. Food and Drug Administration (FDA) approvals of anti-amyloid ...

01/07/2026

In 2018 alone, 9.6 million lives were lost to cancer, making it the second leading cause of death globally.

At Anogen, we believe the future of cancer therapy lies in personalization. Immune checkpoint inhibitors—such as PD-1 and PD-L1–targeted therapies, hold tremendous promise, especially when tailored to the unique immune profile of each patient.

By supporting research in PD-1/PD-L1 checkpoint pathways, we aim to empower scientists to advance more precise, effective, and patient-specific cancer treatments.

🔬 Personalized immunotherapy starts with better research tools.

https://www.youtube.com/watch?v=9AIJAGjVkOc

In 2018, 9.6 million people died from cancer, the second largest cause of death worldwide. Finding a cure to cancer has been the focus of medical science for...

12/18/2025

As the year comes to a close, we’d like to thank our customers, partners, and researchers around the world for your trust and collaboration throughout 2025.

We’re proud to support your work in immunology, oncology, neuroscience, and beyond, and we look forward to continuing this journey together in the year ahead.

Wishing you a joyful holiday season and a successful, inspiring New Year!

🎄❄️✨

12/03/2025

Latest data from the 2025 CTAD conference shows that Eisai’s anti-tau antibody Etalanetug (E2814) dramatically reduces eMTBR-tau243 levels — a blood and CSF biomarker tightly linked to tau tangles — in patients with inherited Alzheimer’s disease. Results suggest tau spreading was inhibited, hinting at real disease-modifying potential for tauopathies.

📉 CSF tau-tangle biomarker down ~62 % at 3 months
📉 Plasma biomarker down ~78 % at 3 months, improving over time

This could pave the way for blood-based monitoring of tau pathology and new therapeutic strategies for Alzheimer’s and related tau disorders.

Read the full article here: https://media-us.eisai.com/2025-12-01-Eisai-Presents-New-Data-on-Anti-Tau-Antibody-Etalanetug-E2814-at-CTAD-2025

Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in Phase Ib/II study TOKYO, Dec. 1, 2025 /PRNewswire/ -- Eisai...

11/26/2025

New insights in immune-modulation! A recent Journal of Leukocyte Biology review highlights how anti-TNF therapy doesn’t just neutralize TNF-α — it also reprograms innate immune cells, offering hope for treating systemic autoinflammatory diseases. 🔄 By targeting the root of inflammation, this approach could reshape standards for immune-disease treatment.

Read the full article here: https://academic.oup.com/jleukbio/article-abstract/117/5/qiaf026/8078379

This review explores the clinical relevance of anti-tumor necrosis factor therapy in systemic autoinflammatory diseases, focusing on its impact on innate i

11/19/2025

🔬 New must-read for Alzheimer’s researchers! A fresh review in Alzheimer’s Disease: Clinical Trials to Watch spotlights next-gen therapies tackling tau, amyloid-β, and neuro-inflammation. Better trial design + smarter biomarkers = real hope for AD.
🔗 https://www.sciencedirect.com/science/article/abs/pii/S2666634025001989

11/12/2025

Tsutomu Takeuchi’s article highlights next-gen anti-TNF agents, including nanobody therapeutics like Ozoralizumab, and what’s “new vs old” in RA treatment. Dive into the evolving pipeline and future of TNF-targeted therapy.

Read the full article: https://pubmed.ncbi.nlm.nih.gov/40180877/

This review summarizes the recent advancement of fragmented immunoglobulin molecules targeting on Tumot Necrosis Factor (TNF) alpha and highlighted the nanobody, which is the first approved product for the patients with rheumatoid arthritis (RA), ozoralizumab (OZR). Background for the clinical devel...

11/05/2025

The FDA now allows patients with multiple sclerosis to self-administer the intranasal antibody Foralumab at home — a first of its kind in anti-CD3 therapy.

This breakthrough drug modulates T-cell activity via nasal delivery, offering a more convenient alternative to clinic-based infusions and potentially boosting patient adherence and outcomes.

With strong safety signals and promising early efficacy in na-SPMS patients, this shift into home dosing could transform how MS is managed.

🔗 Read more: https://www.globenewswire.com/news-release/2023/10/18/2762186/0/en/Tiziana-Life-Sciences-Announces-Allowance-By-FDA-For-At-Home-Dosing-Of-Intranasal-Foralumab-For-Multiple-Sclerosis-Treatment.html?utm_source=chatgpt.com

10/29/2025

A recent Nature Communications (IF 15.4) study by Bao et al., Shanghai Jiao Tong University introduces a groundbreaking neuromorphic electro-stimulation (ES) approach based on atomically thin semiconductors.
This innovation successfully suppresses inflammation without tissue damage, offering a new paradigm for bioelectronic medicine.

📊 Using Anogen’s Mouse ELISA Kits —
• TNF-α (MEC1003)
• IL-6 (MEC1008)
• IL-1β (MEC1010)
the researchers quantitatively confirmed dramatic reductions in pro-inflammatory cytokines:
IL-6 decreased by up to 73.5% after neuromorphic stimulation compared with non-stimulated controls.

🧩 The ELISA data provided by Anogen kits were critical in:

Revealing the Adrb2-dependent signaling mechanism underlying inflammation modulation (Fig. 1e–g)

These results underscore how Anogen’s high-sensitivity cytokine ELISA kits empower researchers to quantify subtle immune responses with precision — supporting world-class innovations in immunology, neuroscience, and bioelectronics.

📖 Bao R., Wang S., et al. (2024). “Neuromorphic electro-stimulation based on atomically thin semiconductor for damage-free inflammation inhibition.” Nature Communications 15, 1327.

🔗 Read on PubMed： https://www.nature.com/articles/s41467-024-45590-8

🔗 Explore Anogen ELISA Kits：https://www.anogen.ca

10/22/2025

A recent study takes a deep look at the evolving therapeutic landscape of tauopathies, a group of neurodegenerative diseases driven by abnormal tau protein aggregation.

📊 Researchers identified around 170 drug candidates currently in development — including 5 in Phase III, 15 in Phase II, and 12 in Phase I clinical trials. While no disease-modifying treatments have been approved yet, the field remains highly active.

🔍 The paper also highlights progress in tau PET imaging biomarkers, with one FDA-approved tracer (Tauvid™) and several others advancing through development — a key step toward better diagnosis and trial monitoring.

Although challenges remain, these findings underscore steady momentum and growing optimism in the fight against tau-related neurodegenerative disorders.

Read the full article: https://pubmed.ncbi.nlm.nih.gov/40462159/

Microtubule associated protein tau (MAPT) is a naturally occurring protein that plays a significant role in stabilizing microtubules, which are essential for the transport of nutrients and other materials within neurons. In tauopathies, tau protein assembles into mis-folded multimers ranging from so...